Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study

Abstract

Purpose

ENESTfreedom is evaluating treatment-free remission (TFR) following frontline nilotinib in patients with chronic myeloid leukemia (CML) in chronic phase. Following our primary analysis at 48 weeks, we here provide an updated 96-week analysis.

Methods

Attempting TFR required ≥ 3 years of nilotinib, a molecular response of MR^4.5 [BCR-ABL1 ≤ 0.0032% on the International Scale (BCR-ABL1^IS)], and sustained deep molecular response (DMR) during a 1-year consolidation phase. Patients restarted nilotinib following loss of major molecular response (MMR; BCR-ABL1^IS ≤ 0.1%).

Results

Ninety-six weeks after stopping treatment (3.6-year median prior nilotinib duration), 93 of 190 patients (48.9%) remained in TFR. Of 88 patients who restarted nilotinib following loss of MMR, 87 regained MMR and 81 regained MR^4.5 by the data cut-off. Ninety-six-week TFR rates were 61.3, 50.0, and 28.6% in patients with low, intermediate, and high Sokal risk scores at diagnosis, respectively. Patients consistently in MR^4.5 during consolidation had higher TFR rates (50.6%) than patients with ≥ 1 assessment without MR^4.5 during consolidation (35.0%). In a landmark analysis, 96-week TFR rates for patients with MR^4.5, MR⁴ (BCR-ABL1^IS ≤ 0.01%) but not MR^4.5, and MMR but not MR⁴ at TFR week 12 were 82.6, 23.1, and 0%, respectively. There were no reports of disease progression or death due to CML; overall adverse event frequency decreased following TFR. Within the follow-up period, TFR did not adversely affect disease outcomes.

Conclusions

These results demonstrate the feasibility and durability of TFR following frontline nilotinib and emphasize the importance of sustained DMR for TFR.

from Cancer via ola Kala on Inoreader https://ift.tt/2Fg7wzm
via IFTTT